Security key
252828108
Dianthus Therapeutics, Inc. /DE/ - Common Stock (DNTH)
CUSIP: 252828108
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock
- Total 13F shares
- 46,828,772
- Total 13F value
- $1,842,663,442
- Share change
- +7,737,001
- Put/Call ratio
- 97%
- SEC-reported price per share
- $39.35
- Number of holders
- 140
- Value change
- +$358,133,968
- Number of buys
- 94
- Number of sells
- 46
- Shares outstanding
- 54,752,594
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q3 2025
Institutions
140
Top holders
10
DNTH full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q2 2026
Dianthus Therapeutics, Inc. /DE/ SEC filings
Dianthus Therapeutics, Inc. /DE/ company facts
Broader feeds
Reporting periods
Holder history for CUSIP 252828108
Recent filing periods:
Ownership snapshot
Top reported holders of DNTH - Dianthus Therapeutics, Inc. /DE/ - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
3/4/5
Lead comparable stake: 15%
13D/G row: FMR LLC
Showing 1-6 of 15 holder rows.
Quick read
FMR LLC leads the comparable SEC ownership view at 15%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens FMR LLC's linked filing trail.
Comparable ownership
Top 5
FMR LLC
15%
TCG Crossover GP II, LLC
4.7%
BCLS Fund III Investments, LP
3.1%
Venrock Healthcare Capital Partne...
3.1%
Vestal Point Capital, LP
3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| FMR LLC |
13D/G
13F
Company
|
15%
|
$234,944,605
5,970,638 shares
|
+$58,553,941 | 30 Sep 2025 |
| TCG Crossover GP II, LLC |
13D/G
|
4.7%
|
$32,660,322
1,501,624 shares
|
$0 | 31 Mar 2025 |
| BCLS Fund III Investments, LP |
13D/G
|
3.1%
|
$51,780,350
1,315,892 shares
|
-$45,896,187 | 30 Sep 2025 |
| Venrock Healthcare Capital Partners III, L.P. |
13D/G
|
3.1%
|
$20,060,000
1,000,000 shares
|
$0 | 30 Jun 2025 |
| Vestal Point Capital, LP |
13F
13D/G
Company
|
3%
from 13D/G
|
$59,616,000
3,200,000 shares
|
— | 30 Jun 2025 |
| RA CAPITAL MANAGEMENT, L.P. |
13F
Company
|
5.2%
|
$53,407,236
2,866,733 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
140
Shares
46,828,772
Rows available
140
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
101
Q3 2025 holders
140
Holder diff
39
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend